Cantor Fitzgerald Downgrades Outlook Therapeutics to Neutral, Lowers Price Target to $1
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Kristen Kluska has downgraded Outlook Therapeutics (NASDAQ:OTLK) from Overweight to Neutral and lowered the price target from $4.5 to $1.
August 30, 2023 | 4:09 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Outlook Therapeutics has been downgraded from Overweight to Neutral by Cantor Fitzgerald, with a lowered price target from $4.5 to $1.
The downgrade from Overweight to Neutral by Cantor Fitzgerald, along with a significant reduction in the price target, indicates a less optimistic outlook for the company. This could potentially lead to a decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100